NEOS - Neos Therapeutics Stock Price, News & Analysis

$9.75 -0.05 (-0.51 %)
(As of 11/23/2017 04:00 PM ET)
Previous Close$9.80
Today's Range$9.45 - $10.00
52-Week Range$4.85 - $13.15
Volume577,300 shs
Average Volume558,360 shs
Market Capitalization$284.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.75

About Neos Therapeutics (NASDAQ:NEOS)

Neos Therapeutics logoNeos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.


Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEOS
CUSIPN/A

Debt

Debt-to-Equity Ratio4.01%
Current Ratio2.42%
Quick Ratio2.14%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.15 million
Price / Sales30.90
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book19.12

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS($3.42)
Net Income$-83,330,000.00
Net Margins-339.52%
Return on Equity-551.26%
Return on Assets-68.57%

Miscellaneous

Employees134
Outstanding Shares29,000,000

Frequently Asked Questions for Neos Therapeutics (NASDAQ:NEOS)

What is Neos Therapeutics' stock symbol?

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

How were Neos Therapeutics' earnings last quarter?

Neos Therapeutics, Inc. (NASDAQ:NEOS) announced its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.22. The business had revenue of $6.70 million for the quarter. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. View Neos Therapeutics' Earnings History.

Where is Neos Therapeutics' stock going? Where will Neos Therapeutics' stock price be in 2017?

5 analysts have issued 1 year price objectives for Neos Therapeutics' stock. Their forecasts range from $12.00 to $20.00. On average, they expect Neos Therapeutics' stock price to reach $16.20 in the next year. View Analyst Ratings for Neos Therapeutics.

What are Wall Street analysts saying about Neos Therapeutics stock?

Here are some recent quotes from research analysts about Neos Therapeutics stock:

  • 1. According to Zacks Investment Research, "Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. " (10/31/2017)
  • 2. Cantor Fitzgerald analysts commented, "CELG shares are trading -15% in the premarket today on reduced guidance, in spite of an EPS beat (reported non-GAAP 3Q17 EPS of $1.91, versus our $1.90 estimate and $1.87 for Factset consensus)." (10/26/2017)

Who are some of Neos Therapeutics' key competitors?

Who are Neos Therapeutics' key executives?

Neos Therapeutics' management team includes the folowing people:

  • Alan Heller, Chairman of the Board (Age 61)
  • Vipin K. Garg Ph.D., President, Chief Executive Officer, Director (Age 58)
  • Richard Eisenstadt, Chief Financial Officer (Age 56)
  • Dorothy Engelking, Vice President of Regulatory Affairs (Age 55)
  • Thomas P McDonnell, Chief Commercial Officer (Age 43)
  • Beth P. Hecht, Director
  • Paul R. Edick, Non-Executive Director (Age 62)
  • Bryant E. Fong, Non-Executive Director
  • Gregory J. Robitaille, Non-Executive Director
  • John P. Schmid, Non-Executive Director (Age 53)

When did Neos Therapeutics IPO?

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Who owns Neos Therapeutics stock?

Neos Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include FLYNN JAMES E (9.08%), Cortina Asset Management LLC (2.12%), Essex Investment Management Co. LLC (0.85%), Lyon Street Capital LLC (0.78%), Columbus Circle Investors (0.63%) and Wells Fargo & Company MN (0.43%). Company insiders that own Neos Therapeutics stock include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Presidio Partners 2007, LP, Richard I Eisenstadt and Thomas P Mcdonnell. View Institutional Ownership Trends for Neos Therapeutics.

Who sold Neos Therapeutics stock? Who is selling Neos Therapeutics stock?

Neos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors. View Insider Buying and Selling for Neos Therapeutics.

Who bought Neos Therapeutics stock? Who is buying Neos Therapeutics stock?

Neos Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Lyon Street Capital LLC, Sheaff Brock Investment Advisors LLC, Citadel Advisors LLC, Wells Fargo & Company MN, Essex Investment Management Co. LLC, Bank of New York Mellon Corp and JPMorgan Chase & Co.. Company insiders that have bought Neos Therapeutics stock in the last two years include Alan L Heller, Bryant Fong, Gregory J Robitaille, Juergen Martens, Richard I Eisenstadt and Thomas P Mcdonnell. View Insider Buying and Selling for Neos Therapeutics.

How do I buy Neos Therapeutics stock?

Shares of Neos Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neos Therapeutics' stock price today?

One share of Neos Therapeutics stock can currently be purchased for approximately $9.75.

How big of a company is Neos Therapeutics?

Neos Therapeutics has a market capitalization of $284.17 million and generates $9.15 million in revenue each year. The company earns $-83,330,000.00 in net income (profit) each year or ($3.42) on an earnings per share basis. Neos Therapeutics employs 134 workers across the globe.

How can I contact Neos Therapeutics?

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300.


MarketBeat Community Rating for Neos Therapeutics (NEOS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Neos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Neos Therapeutics (NASDAQ:NEOS)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.20 (66.15% upside)

Consensus Price Target History for Neos Therapeutics (NASDAQ:NEOS)

Price Target History for Neos Therapeutics (NASDAQ:NEOS)

Analysts' Ratings History for Neos Therapeutics (NASDAQ:NEOS)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017Cantor FitzgeraldSet Price TargetBuy$20.00N/AView Rating Details
10/26/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
10/18/2017Wells Fargo & CompanySet Price TargetBuy$14.00N/AView Rating Details
8/8/2017Royal Bank Of CanadaSet Price TargetOutperform$12.00MediumView Rating Details
6/20/2017BMO Capital MarketsReiterated RatingOutperform$15.00HighView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$33.00 -> $32.00N/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Neos Therapeutics (NASDAQ:NEOS)

Earnings by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Earnings History by Quarter for Neos Therapeutics (NASDAQ NEOS)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.80)($0.58)$6.70 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.83)($0.83)$4.91 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.94)($0.87)$5.63 millionViewListenView Earnings Details
3/14/2017Q4 2016($1.36)($1.14)$3.50 millionViewN/AView Earnings Details
11/10/2016Q3 2016($1.64)($1.61)$1.58 millionViewN/AView Earnings Details
8/11/2016Q2($1.16)($1.65)$1.48 million$1.49 millionViewListenView Earnings Details
5/16/2016Q1($0.87)($0.79)$1.50 million$2.58 millionViewListenView Earnings Details
3/17/2016Q4($0.66)($0.57)$1.70 millionViewListenView Earnings Details
9/3/2015Q215($4.31)($7.76)$1.70 million$1.48 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neos Therapeutics (NASDAQ:NEOS)
Current Year EPS Consensus Estimate: $-2.87 EPS
Next Year EPS Consensus Estimate: $-1.59 EPS

Dividends

Dividend History for Neos Therapeutics (NASDAQ:NEOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neos Therapeutics (NASDAQ NEOS)

Insider Ownership Percentage: 5.17%
Institutional Ownership Percentage: 45.13%
Insider Trades by Quarter for Neos Therapeutics (NASDAQ:NEOS)
Institutional Ownership by Quarter for Neos Therapeutics (NASDAQ:NEOS)

Insider Trades by Quarter for Neos Therapeutics (NASDAQ NEOS)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2016Bryant FongDirectorBuy1,500$6.54$9,810.00View SEC Filing  
8/25/2016Richard I EisenstadtCFOBuy3,710$6.82$25,302.20View SEC Filing  
6/13/2016Juergen MartensInsiderBuy10,000$9.90$99,000.00View SEC Filing  
5/19/2016Alan L HellerDirectorBuy10,000$7.61$76,100.00View SEC Filing  
5/19/2016Thomas P McdonnellInsiderBuy3,000$7.56$22,680.00View SEC Filing  
5/18/2016Gregory J RobitailleDirectorBuy7,442$7.55$56,187.10View SEC Filing  
4/20/2016Presidio Partners 2007, L.P.Major ShareholderSell20,367$9.98$203,262.66View SEC Filing  
4/15/2016Presidio Partners 2007, L.P.Major ShareholderSell57,968$10.23$593,012.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Neos Therapeutics (NASDAQ NEOS)

Source:
DateHeadline
Zacks: Analysts Expect Neos Therapeutics, Inc. (NEOS) Will Announce Earnings of -$0.60 Per ShareZacks: Analysts Expect Neos Therapeutics, Inc. (NEOS) Will Announce Earnings of -$0.60 Per Share
www.americanbankingnews.com - November 11 at 3:28 PM
Neos Therapeutics, Inc. (NEOS) Posts Quarterly  Earnings Results, Beats Estimates By $0.22 EPSNeos Therapeutics, Inc. (NEOS) Posts Quarterly Earnings Results, Beats Estimates By $0.22 EPS
www.americanbankingnews.com - November 10 at 7:09 PM
PDL BioPharmas Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale ... - PR Newswire (press release)PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale ... - PR Newswire (press release)
www.prnewswire.com - November 9 at 7:44 AM
Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 9 at 7:43 AM
Why Neos Therapeutics Inc Rose 13.7% In October - Motley FoolWhy Neos Therapeutics Inc Rose 13.7% In October - Motley Fool
www.fool.com - November 9 at 7:43 AM
Neos Therapeutics Reports Third Quarter 2017 Financial ResultsNeos Therapeutics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 7:43 AM
PDL BioPharmas Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale ProcessPDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
finance.yahoo.com - November 9 at 7:43 AM
Neos Therapeutics reports 3Q lossNeos Therapeutics reports 3Q loss
finance.yahoo.com - November 9 at 7:43 AM
Edited Transcript of NEOS earnings conference call or presentation 8-Nov-17 1:30pm GMTEdited Transcript of NEOS earnings conference call or presentation 8-Nov-17 1:30pm GMT
finance.yahoo.com - November 9 at 7:43 AM
Neos Therapeutics Inc (NEOS) Receives Average Rating of "Buy" from BrokeragesNeos Therapeutics Inc (NEOS) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 8 at 2:06 AM
Neos Therapeutics to Host Third Quarter 2017 Financial Results Conference Call on November 8, 2017Neos Therapeutics to Host Third Quarter 2017 Financial Results Conference Call on November 8, 2017
finance.yahoo.com - November 4 at 7:50 AM
Wall Streets M&A Chatter From October 31: Neos Therapeutics, Rockwell Automation-Emerson Electric, Charter - BenzingaWall Street's M&A Chatter From October 31: Neos Therapeutics, Rockwell Automation-Emerson Electric, Charter - Benzinga
www.benzinga.com - November 2 at 6:48 AM
Cantor Fitzgerald Analysts Give Neos Therapeutics, Inc. (NEOS) a $20.00 Price TargetCantor Fitzgerald Analysts Give Neos Therapeutics, Inc. (NEOS) a $20.00 Price Target
www.americanbankingnews.com - November 1 at 1:54 PM
Neos Therapeutics to consider other offers after PDL snub: sources - ReutersNeos Therapeutics to consider other offers after PDL snub: sources - Reuters
www.reuters.com - November 1 at 6:42 AM
Neos Therapeutics to consider other offers after PDL snub -sourcesNeos Therapeutics to consider other offers after PDL snub -sources
finance.yahoo.com - November 1 at 6:42 AM
Neos Therapeutics, Inc. (NEOS) Scheduled to Post Quarterly Earnings on WednesdayNeos Therapeutics, Inc. (NEOS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:28 AM
Neos Therapeutics (NEOS) Rejects Unsolicited Proposal from PDL BioPharma (PDLI) - StreetInsider.comNeos Therapeutics (NEOS) Rejects Unsolicited Proposal from PDL BioPharma (PDLI) - StreetInsider.com
www.streetinsider.com - October 31 at 6:51 AM
PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition ProposalPDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
finance.yahoo.com - October 31 at 6:51 AM
Neos Therapeutics (NEOS) Says it Will Review Unsolicited Proposal from PDL BioPharma (PDLI)Neos Therapeutics (NEOS) Says it Will Review Unsolicited Proposal from PDL BioPharma (PDLI)
www.streetinsider.com - October 27 at 8:26 AM
Neos Therapeutics To Review Proposal From PDL BioPharmaNeos Therapeutics To Review Proposal From PDL BioPharma
www.rttnews.com - October 27 at 8:26 AM
PDLs Offer For Neos Therapeutics Could Be Too LowPDL's Offer For Neos Therapeutics Could Be Too Low
www.benzinga.com - October 27 at 8:26 AM
BRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL BiopharmaBRIEF-Neos Therapeutics‍ confirms it got unsolicited proposal from PDL Biopharma
www.reuters.com - October 27 at 8:26 AM
PDL BioPharma Proposes to Acquire Neos Therapeutics for $10.25 per Share in CashPDL BioPharma Proposes to Acquire Neos Therapeutics for $10.25 per Share in Cash
finance.yahoo.com - October 27 at 8:26 AM
PDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premiumPDL BioPharma makes unsolicited bid to buy Neos Therapeutics for a 40% premium
finance.yahoo.com - October 27 at 8:26 AM
Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharmaNeos Therapeutics to Review Unsolicited Proposal from PDL BioPharma
finance.yahoo.com - October 27 at 8:26 AM
Neos Therapeutics stock rockets after buyout bid, says it will respond in due courseNeos Therapeutics' stock rockets after buyout bid, says it will respond in 'due course'
finance.yahoo.com - October 27 at 8:26 AM
Neos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharmaNeos Therapeutics Stock Soars on 3rd Unsolicited Buyout Offer From PDL BioPharma
finance.yahoo.com - October 27 at 8:26 AM
Why Neos Therapeutics Inc (NEOS) Shares Climbed 37% TodayWhy Neos Therapeutics Inc (NEOS) Shares Climbed 37% Today
finance.yahoo.com - October 27 at 8:26 AM
Todays Research Reports on Stocks to Watch: Neos Therapeutics and INSYS TherapeuticsToday's Research Reports on Stocks to Watch: Neos Therapeutics and INSYS Therapeutics
finance.yahoo.com - October 27 at 8:26 AM
Neos Therapeutics, Inc. (NEOS) Earns Buy Rating from Cantor FitzgeraldNeos Therapeutics, Inc. (NEOS) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - October 26 at 10:00 AM
Neos Therapeutics to Present Two Posters on Company’s ADHD Medications at the American Academy of Child & Adolescent Psychiatry MeetingNeos Therapeutics to Present Two Posters on Company’s ADHD Medications at the American Academy of Child & Adolescent Psychiatry Meeting
finance.yahoo.com - October 25 at 8:04 AM
 Brokerages Anticipate Neos Therapeutics, Inc. (NEOS) Will Announce Earnings of -$0.70 Per Share Brokerages Anticipate Neos Therapeutics, Inc. (NEOS) Will Announce Earnings of -$0.70 Per Share
www.americanbankingnews.com - October 22 at 2:04 PM
Neos Therapeutics Enters Oversold Territory (NEOS)Neos Therapeutics Enters Oversold Territory (NEOS)
www.thestreet.com - October 21 at 6:58 AM
Neos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT® Patent LitigationNeos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT® Patent Litigation
globenewswire.com - October 19 at 6:44 AM
Cantor Fitzgerald Reiterates $20.00 Price Target for Neos Therapeutics, Inc. (NEOS)Cantor Fitzgerald Reiterates $20.00 Price Target for Neos Therapeutics, Inc. (NEOS)
www.americanbankingnews.com - October 18 at 8:22 PM
Wells Fargo & Company Analysts Give Neos Therapeutics, Inc. (NEOS) a $14.00 Price TargetWells Fargo & Company Analysts Give Neos Therapeutics, Inc. (NEOS) a $14.00 Price Target
www.americanbankingnews.com - October 18 at 3:08 PM
Neos Therapeutics (NEOS) & Bristol-Myers Squibb (BMY) Head-To-Head ComparisonNeos Therapeutics (NEOS) & Bristol-Myers Squibb (BMY) Head-To-Head Comparison
www.americanbankingnews.com - October 17 at 6:24 PM
Neos Therapeutics, Inc. (NEOS) Receives Average Rating of "Hold" from AnalystsNeos Therapeutics, Inc. (NEOS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 14 at 2:58 AM
Reviewing Neos Therapeutics (NEOS) and BioLife Solutions (BLFS)Reviewing Neos Therapeutics (NEOS) and BioLife Solutions (BLFS)
www.americanbankingnews.com - October 10 at 12:18 AM
Neos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally ... - GlobeNewswire (press release)Neos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally ... - GlobeNewswire (press release)
globenewswire.com - October 2 at 10:54 PM
Neos Therapeutics (NEOS) vs. Its Rivals Head-To-Head ComparisonNeos Therapeutics (NEOS) vs. Its Rivals Head-To-Head Comparison
www.americanbankingnews.com - October 1 at 10:22 AM
Cantor Fitzgerald Reaffirms "Buy" Rating for Neos Therapeutics, Inc. (NEOS)Cantor Fitzgerald Reaffirms "Buy" Rating for Neos Therapeutics, Inc. (NEOS)
www.americanbankingnews.com - September 26 at 4:24 PM
Financial Analysis: Neos Therapeutics (NEOS) versus Its RivalsFinancial Analysis: Neos Therapeutics (NEOS) versus Its Rivals
www.americanbankingnews.com - September 26 at 6:24 AM
Comparing Neos Therapeutics (NEOS) & Bristol-Myers Squibb (BMY)Comparing Neos Therapeutics (NEOS) & Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - September 22 at 6:26 PM
Corporate News Blog - Neos Therapeutics Receives FDA’s Approval for Adzenys ER(TM) Extended-Release Oral Suspension, its Third Treatment for ADHDCorporate News Blog - Neos Therapeutics Receives FDA’s Approval for Adzenys ER(TM) Extended-Release Oral Suspension, its Third Treatment for ADHD
finance.yahoo.com - September 20 at 6:53 AM
Neos Therapeutics (NEOS) versus The Competition Head to Head AnalysisNeos Therapeutics (NEOS) versus The Competition Head to Head Analysis
www.americanbankingnews.com - September 19 at 2:30 PM
Neos Therapeutics, Inc. (NEOS) Receives Consensus Recommendation of "Hold" from AnalystsNeos Therapeutics, Inc. (NEOS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 19 at 2:38 AM
Financial Comparison: Neos Therapeutics (NEOS) vs. Its CompetitorsFinancial Comparison: Neos Therapeutics (NEOS) vs. Its Competitors
www.americanbankingnews.com - September 17 at 4:26 AM
Neos Therapeutics (NEOS) Granted U.S. FDA Approval of Adzenys ER (amphetamineNeos Therapeutics (NEOS) Granted U.S. FDA Approval of Adzenys ER (amphetamine
www.streetinsider.com - September 17 at 2:06 AM
Neos Therapeutics to launch third medication in ADHD franchise in January 2018Neos Therapeutics to launch third medication in ADHD franchise in January 2018
www.nasdaq.com - September 16 at 6:54 AM

Social Media

Financials

Chart

Neos Therapeutics (NASDAQ NEOS) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.